Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Bacopa Monnieri and Huperzine A are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
1 of 1 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
4 of 5 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (3)
Outcomes where both Bacopa Monnieri and Huperzine A have evidence — compare verdict strength side-by-side.
300-450mg daily (standardized to 50% bacosides)
With fatty meal for absorption
Bacognize® or Synapsa® standardized extract
50-200mcg twice daily
Morning and early afternoon, Avoid evening (may cause vivid dreams)
Huperzine A capsules (standardized extract)
8-12 weeks
8-12 weeks
First 2 weeks
First week
2-4 weeks
30-60 minutes
2-4 weeks
During use
Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review
Nutrients (2025) · Systematic review
The evidence revealed the potential use of supplements as complementary ADHD treatments under clinical guidance.
Effectiveness of Bacopa Monnieri (Brahmi) in the management of schizophrenia: a systematic review
Nutritional neuroscience (2025) · Systematic review · n=103
Schizophrenia is a psychotic disorder affecting approximately 0.32% of the global population.
Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability
Nutrients (2025) · Systematic review
Animal studies have shown promising results in reducing symptoms and protecting against neurodegeneration.
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Traditional Chinese herbal medicine for vascular dementia
The Cochrane database of systematic reviews (2018) · Systematic review · n=3581
Two TCHMs (NaoMaiTai and TongXinLuo) had a 5% or more increased risk of AEs compared to the 'no Treatment' control, but the quality of this evidence was poor.
Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews
BMJ open (2016) · Systematic review · n=289
The quality of the reviews varied; however most (65%) scored 8/11 or more on the AMSTAR tool, indicating high quality.
Based on meta-analysis of 437 participants showing improvements in attention, processing speed, and working memory. However, one large RCT (n=101) found no significant between-group differences. Effects may take 8-12 weeks to manifest. Standardized extracts (Bacognize, Synapsa) may have better bioavailability than generic forms.
Based on meta-analysis showing MMSE improvement (WMD: 2.27) in dementia populations. Evidence primarily from dementia patients, limited data in healthy individuals. Quality concerns noted in systematic reviews regarding study methodology.
AI-estimated from published studies. Interpret as directional guidance.
Both Bacopa Monnieri and Huperzine A are closely matched — the best choice depends on your specific health goals.
For improve memory & learning, Bacopa Monnieri has a higher relevance score (95 vs 72).
No known interactions between Bacopa Monnieri and Huperzine A have been documented in our database. However, always consult a healthcare provider before combining supplements.